Clinical Trials · NCT07575399

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Name: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Maridebart cafraglutide

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Amgen
Enrollment: 300
Start date: May 2026
Locations: 43 sites, United States, Puerto Rico
Primary endpoint: Percent Change from Baseline in Body Weight at Week 68

View Maridebart-Cafraglutide compound reference